NCT06927739 (FORTIFY) is a Phase 2 clinical trial of Orticumab in Acute Coronary Syndromes, sponsored by Abcentra.

Who is sponsoring NCT06927739?

NCT06927739 is sponsored by Abcentra.

What drugs are being tested in NCT06927739?

Interventions in NCT06927739: Orticumab, Placebo.

What condition does NCT06927739 study?

NCT06927739 studies Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease.

Is NCT06927739 still recruiting?

NCT06927739 is currently recruiting now. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT06927739: FORTIFY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Recruiting now Phase 2 Last updated 27 January 2026

What this trial tests

Phase 2 trial testing Orticumab in Acute Coronary Syndromes in 240 participants. Currently enrolling.

Timeline

11 August 2025

Primary endpoint
8 February 2027

1 June 2027

Quick facts

Lead sponsor	Abcentra
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	240
Start date	11 August 2025
Primary completion	8 February 2027
Estimated completion	1 June 2027
Sites	41 locations across Italy, Sweden, United Kingdom, Poland, Hungary, Romania, United States, Spain

Drugs / interventions tested

Orticumab — full drug profile →
Placebo

Conditions studied

Acute Coronary Syndromes — all drugs for Acute Coronary Syndromes →
Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →
Inflammation — all drugs for Inflammation →
Heart Disease — all drugs for Heart Disease →

Sponsor

Abcentra

Who can join

18 and older, any sex, with Acute Coronary Syndromes or Coronary Arterial Disease (CAD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis.
Choudhury RP, Hargreaves R, Chai J, Fisher EA. · · 2025 · PMID 40782797 · DOI 10.1016/j.xcrm.2025.102288
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy.
Farina CJ, Lu W, Nilsson J. · · 2025 · PMID 40293233 · DOI 10.1097/mol.0000000000000990

Verify or expand the search:

Other trials of Orticumab

Trials testing the same drug.

NCT04776629 — A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors · Phase 2 · completed

Other recruiting trials for Acute Coronary Syndromes

Currently open trials in the same condition.

NCT07123181 — Oregano and Basil Leaves and Coronary Artery Disease · NA · recruiting
NCT06845826 — Point-of-Care Troponin Testing in the Emergency Department · NA · recruiting
NCT07268859 — Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea · NA · recruiting
NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting
NCT06813339 — Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients · EARLY_PHASE1 · recruiting

Other Abcentra trials

Trials by the same sponsor.

NCT04776629 — A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06927739 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abcentra
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06927739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing